This list is an analysis based on recent market events. It's not an investment recommendation.
Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade. The company was formerly known as Bridge Biotherapeutics, Inc. and changed its name to Parataxis Korea, Inc. in August 2025. The company was founded in 2015 and is headquartered in Seongnam-si, South Korea.
FAQs
What is Parataxis Korea stock price today?▼
The current price of 288330.KQ is ₩416 KRW — it has decreased by -3.03% in the past 24 hours. Watch Parataxis Korea stock price performance more closely on the chart.
What is Parataxis Korea stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on KOSDAQ exchange Parataxis Korea stocks are traded under the ticker 288330.KQ.
Is Parataxis Korea stock price growing?▼
288330.KQ stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Parataxis Korea has showed a -69.05% decrease.
What is Parataxis Korea market cap?▼
Today Parataxis Korea has the market capitalization of 44.13B
What were Parataxis Korea earnings last quarter?▼
288330.KQ earnings for the last quarter are -281 KRW per share, whereas the estimation was N/A KRW resulting in a N/A surprise. The estimated earnings for the next quarter are N/A KRW per share.
What is Parataxis Korea revenue for the last year?▼
Parataxis Korea revenue for the last year amounts to 319.22M KRW.
What is Parataxis Korea net income for the last year?▼
288330.KQ net income for the last year is -2.58B KRW.
How many employees does Parataxis Korea have?▼
As of November 3, 2026, the company has 21 employees.
In which sector is Parataxis Korea located?▼
Parataxis Korea operates in the Energy sector.
When did Parataxis Korea complete a stock split?▼
The last stock split for Parataxis Korea was on July 29, 2024 with a ratio of 1.2:1.
Where is Parataxis Korea headquartered?▼
Parataxis Korea is headquartered in Seongnam-si, South Korea.